IL230391B - Combination als therapy - Google Patents
Combination als therapyInfo
- Publication number
- IL230391B IL230391B IL230391A IL23039114A IL230391B IL 230391 B IL230391 B IL 230391B IL 230391 A IL230391 A IL 230391A IL 23039114 A IL23039114 A IL 23039114A IL 230391 B IL230391 B IL 230391B
- Authority
- IL
- Israel
- Prior art keywords
- als
- combined treatment
- treatment
- combined
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161507381P | 2011-07-13 | 2011-07-13 | |
| US201161544533P | 2011-10-07 | 2011-10-07 | |
| US201261637770P | 2012-04-24 | 2012-04-24 | |
| US201261637759P | 2012-04-24 | 2012-04-24 | |
| US201261646699P | 2012-05-14 | 2012-05-14 | |
| PCT/US2012/046523 WO2013010015A2 (en) | 2011-07-13 | 2012-07-12 | Combination als therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL230391B true IL230391B (en) | 2019-03-31 |
Family
ID=47506929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL230391A IL230391B (en) | 2011-07-13 | 2014-01-09 | Combination als therapy |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10272082B2 (show.php) |
| EP (1) | EP2731611B1 (show.php) |
| JP (2) | JP6145946B2 (show.php) |
| KR (1) | KR101951220B1 (show.php) |
| CN (2) | CN109316480A (show.php) |
| AU (2) | AU2012281042B2 (show.php) |
| BR (1) | BR112014000742A2 (show.php) |
| CA (1) | CA2849213A1 (show.php) |
| EA (2) | EA028060B1 (show.php) |
| HK (1) | HK1197178A1 (show.php) |
| IL (1) | IL230391B (show.php) |
| IN (1) | IN2014DN00200A (show.php) |
| PH (1) | PH12014500094A1 (show.php) |
| SG (1) | SG10201605707UA (show.php) |
| WO (1) | WO2013010015A2 (show.php) |
| ZA (1) | ZA201400236B (show.php) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| WO2015063318A1 (en) * | 2013-11-04 | 2015-05-07 | Ab Science | Use of masitinib for treatment of amyotrophic lateral sclerosis |
| PT3137622T (pt) * | 2014-04-29 | 2022-03-08 | Cytokinetics Inc | Métodos para reduzir o declínio da capacidade vital |
| MX368838B (es) * | 2014-11-21 | 2019-10-18 | Biohaven Pharm Holding Co Ltd | Administracion sublingual de riluzol. |
| WO2016081466A1 (en) * | 2014-11-21 | 2016-05-26 | Biohaven Pharmaceutical Holding Company Ltd. | Sublingual administration of riluzole |
| EP3072513A1 (en) * | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
| PT3240538T (pt) | 2016-03-25 | 2021-12-07 | Ab Science | Uso de masitinib para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica |
| EP4031135A4 (en) * | 2019-09-20 | 2023-10-18 | Icahn School of Medicine at Mount Sinai | CONTROLLED RELEASE FORMULATIONS OF RILUZOLE AND USES THEREOF |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3507866A (en) | 1967-08-08 | 1970-04-21 | Merck & Co Inc | 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation |
| BE788065A (fr) | 1971-08-26 | 1973-02-26 | Degussa | Nouvelles aza-benzimidazoles et procede pour leur preparation |
| IT1156732B (it) | 1978-05-10 | 1987-02-04 | Roussel Maestretti Spa | Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione |
| US4668686A (en) | 1985-04-25 | 1987-05-26 | Bristol-Myers Company | Imidazoquinoline antithrombrogenic cardiotonic agents |
| US4775674A (en) | 1986-05-23 | 1988-10-04 | Bristol-Myers Company | Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors |
| US4943573A (en) | 1989-11-01 | 1990-07-24 | Bristol-Myers Squibb Company | Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility |
| US5354759A (en) | 1991-09-12 | 1994-10-11 | Fujisawa Pharmaceutical Co., Ltd. | Angiotenin II antagonizing heterocyclic compounds |
| JPH0641135A (ja) | 1992-07-21 | 1994-02-15 | Nippon Soda Co Ltd | イミダゾプテリジン誘導体及びその製造方法 |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| JP2002517396A (ja) | 1998-06-04 | 2002-06-18 | アボット・ラボラトリーズ | 細胞接着阻害抗炎症性化合物 |
| CN1257169C (zh) | 1999-10-08 | 2006-05-24 | 格吕伦塔尔有限公司 | 双环咪唑－3－基－胺衍生物 |
| IL149010A0 (en) | 1999-10-08 | 2002-11-10 | Gruenenthal Chemie | Bicyclic imidazo-5-yl-amine derivatives |
| DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| US20030083318A1 (en) * | 2001-10-25 | 2003-05-01 | Jean-Pierre Julien | Therapy for neurodegenerative diseases |
| US20040235801A1 (en) * | 2001-10-25 | 2004-11-25 | Jean-Pierre Julien | Therapy for stroke |
| GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| GB0212048D0 (en) | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
| AU2003294249A1 (en) | 2002-11-08 | 2004-06-03 | Trimeris, Inc. | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| AU2004263080B2 (en) | 2003-06-26 | 2008-12-18 | Merck Sharp & Dohme Corp. | Benzodiazepine CGRP receptor antagonists |
| CA2530081A1 (en) | 2003-07-01 | 2005-01-13 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| WO2005060711A2 (en) | 2003-12-19 | 2005-07-07 | Elixir Pharmaceuticals, Inc. | Methods of treating a disorder |
| US20060019952A1 (en) | 2004-01-29 | 2006-01-26 | Elixir Pharmaceuticals, Inc. | Anti-viral therapeutics |
| WO2005108374A1 (en) | 2004-04-29 | 2005-11-17 | Fmc Corporation | Insecticidal diazole and triazole derivatives |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| JP2008514628A (ja) | 2004-09-24 | 2008-05-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 蛋白質キナーゼ類のイミダゾ｛４，５−ｂ｝ピラジノン阻害剤 |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| CA2598489A1 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Piperazine-piperidines with cxcr3 antagonist activity |
| EP1959962A2 (en) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| WO2007125310A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical combinations of pk inhibitors and other active agents |
| EP3719018B1 (en) | 2006-04-25 | 2025-08-27 | Astex Therapeutics Ltd | Purine and deazapurine derivatives as pharmaceutical compounds |
| WO2008016648A2 (en) | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions and methods |
| US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| US8299248B2 (en) * | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| SI2069352T1 (sl) * | 2006-08-02 | 2013-12-31 | Cytokinetics, Inc. | Določene kemijske entitete, sestavki in postopki |
| CN102993204A (zh) | 2006-08-02 | 2013-03-27 | 赛特凯恩蒂克公司 | 特定的化学个体、组合物和方法 |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| MX337906B (es) | 2006-10-19 | 2016-03-28 | Signal Pharm Llc | Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas. |
| WO2008075007A1 (en) | 2006-12-21 | 2008-06-26 | Cancer Research Technology Limited | Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents |
| AU2008206045A1 (en) | 2007-01-19 | 2008-07-24 | Ardea Biosciences, Inc. | Inhibitors of MEK |
| US7851484B2 (en) | 2007-03-30 | 2010-12-14 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| EP2018854A1 (en) | 2007-07-27 | 2009-01-28 | Merz Pharma GmbH & Co. KGaA | Novel combinations of neramexane for the treatment of neurodegenerative disorders |
| CA2713864A1 (en) | 2008-02-04 | 2009-08-13 | Cytokinetics, Incorporated | Certain chemical entities, compositions and methods |
| US7998976B2 (en) | 2008-02-04 | 2011-08-16 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| EP2323691A2 (en) * | 2008-07-11 | 2011-05-25 | Glaxo Group Limited | Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist |
| CA2744498C (en) | 2008-11-25 | 2017-10-24 | University Of Rochester | Mlk inhibitors and methods of use |
| EP2228054A1 (en) | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
| AU2010262970A1 (en) | 2009-06-19 | 2012-01-12 | Knopp Neurosciences, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
| MX354965B (es) | 2012-04-02 | 2018-03-27 | Cytokinetics Inc | Metodo para mejorar la funcion del diafragma. |
| HK1206389A1 (en) | 2012-04-11 | 2016-01-08 | Cytokinetics, Incorporated | Methods for improving resistance to skeletal muscle fatigue |
| PT3137622T (pt) | 2014-04-29 | 2022-03-08 | Cytokinetics Inc | Métodos para reduzir o declínio da capacidade vital |
-
2012
- 2012-07-12 IN IN200DEN2014 patent/IN2014DN00200A/en unknown
- 2012-07-12 US US14/131,649 patent/US10272082B2/en not_active Expired - Fee Related
- 2012-07-12 AU AU2012281042A patent/AU2012281042B2/en not_active Ceased
- 2012-07-12 JP JP2014520335A patent/JP6145946B2/ja not_active Expired - Fee Related
- 2012-07-12 BR BR112014000742A patent/BR112014000742A2/pt not_active Application Discontinuation
- 2012-07-12 KR KR1020147000783A patent/KR101951220B1/ko not_active Expired - Fee Related
- 2012-07-12 HK HK14110537.3A patent/HK1197178A1/xx unknown
- 2012-07-12 EP EP12811325.5A patent/EP2731611B1/en active Active
- 2012-07-12 SG SG10201605707UA patent/SG10201605707UA/en unknown
- 2012-07-12 CA CA2849213A patent/CA2849213A1/en not_active Abandoned
- 2012-07-12 WO PCT/US2012/046523 patent/WO2013010015A2/en not_active Ceased
- 2012-07-12 EA EA201490011A patent/EA028060B1/ru not_active IP Right Cessation
- 2012-07-12 CN CN201811116043.0A patent/CN109316480A/zh active Pending
- 2012-07-12 PH PH1/2014/500094A patent/PH12014500094A1/en unknown
- 2012-07-12 EA EA201791043A patent/EA201791043A1/ru unknown
- 2012-07-12 CN CN201280034661.5A patent/CN104039148A/zh active Pending
-
2014
- 2014-01-09 IL IL230391A patent/IL230391B/en active IP Right Grant
- 2014-01-10 ZA ZA2014/00236A patent/ZA201400236B/en unknown
-
2016
- 2016-10-13 AU AU2016244263A patent/AU2016244263A1/en not_active Abandoned
-
2017
- 2017-04-28 JP JP2017090313A patent/JP2017128610A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12014500094A1 (en) | 2014-03-17 |
| HK1197178A1 (en) | 2015-01-09 |
| ZA201400236B (en) | 2014-10-29 |
| SG10201605707UA (en) | 2016-09-29 |
| EA028060B1 (ru) | 2017-10-31 |
| WO2013010015A3 (en) | 2014-05-15 |
| US10272082B2 (en) | 2019-04-30 |
| AU2012281042B2 (en) | 2016-07-14 |
| NZ619924A (en) | 2016-02-26 |
| CN109316480A (zh) | 2019-02-12 |
| EP2731611A4 (en) | 2015-02-18 |
| WO2013010015A2 (en) | 2013-01-17 |
| KR20140074270A (ko) | 2014-06-17 |
| EA201791043A1 (ru) | 2017-09-29 |
| IN2014DN00200A (show.php) | 2015-06-05 |
| JP6145946B2 (ja) | 2017-06-14 |
| EA201490011A1 (ru) | 2014-08-29 |
| AU2012281042A1 (en) | 2014-01-30 |
| KR101951220B1 (ko) | 2019-02-22 |
| JP2017128610A (ja) | 2017-07-27 |
| CN104039148A (zh) | 2014-09-10 |
| CA2849213A1 (en) | 2013-01-17 |
| EP2731611A2 (en) | 2014-05-21 |
| BR112014000742A2 (pt) | 2016-08-23 |
| US20140243344A1 (en) | 2014-08-28 |
| JP2014520856A (ja) | 2014-08-25 |
| AU2016244263A1 (en) | 2016-11-03 |
| EP2731611B1 (en) | 2019-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014007603A2 (pt) | métodos de tratamento do câncer | |
| DK2761553T3 (da) | Betalingssystem | |
| EP2698463A4 (en) | WASHING METHOD | |
| LT2707030T (lt) | Vėžio gydymas | |
| EP2663304A4 (en) | COMBINATION THERAPY | |
| HUE046667T2 (hu) | Rák kombinatív kezelése | |
| BRDI7105199S (pt) | Configuração aplicada em bolsa | |
| DK3421470T3 (da) | Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form | |
| BR112013033974A2 (pt) | terapia de combinação | |
| DK2760886T3 (da) | Immunocytokin-kombinationsterapi | |
| IL249039A0 (en) | 2-thiopyrimidinones | |
| EP2725663A4 (en) | CONNECTOR | |
| FI20115876A0 (fi) | Yhdistelmähoito | |
| IL230391B (en) | Combination als therapy | |
| DK2489413T3 (da) | Behandlingsapparat | |
| PT2750709T (pt) | Tratamento da caquexia | |
| FI20115640A0 (fi) | Yhdistelmähoito | |
| EP2763255A4 (en) | Connector | |
| FI20116093L (fi) | Vettä käsittelevä laitos | |
| IL228729A0 (en) | Treatment regimens | |
| CO6950447A2 (es) | Aparato de tratamiento de espalda | |
| DK2607881T3 (da) | Koncentrationsapparat | |
| FI20115020A0 (fi) | Käsittely-yksikkö | |
| FI20115905A0 (fi) | Käsittelyjärjestely | |
| BRDI7103715S (pt) | Configuração aplicada em confeito |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |